The Survey Research Facility (SRF) will provide to Mayo Clinic Cancer Center members support for the conduct of surveys. This support will include expert consultation, instrument development, sampling, mailing, telephoning, response tracking, and instrument processing. Although the Facility has been in existence since 1991, this is the first time it is being proposed as a Cancer Center shared resource. It was identified through a comprehensive review of potential shared resources conducted in 2002. Having conducted over 1,000 survey-based studies since its beginning in 1991, the SRF has experience in many areas pertinent to cancer research (e.g., risk factor assessment, obtaining outcomes following diagnosis or treatment, recruitment for clinical trials, assessing attitudes and behaviors related to cancer screening, assessing the acceptability of cancer screening methods, determination of family trees for genetic studies, assessing satisfaction with cancer related treatment and associated health care encounters, assessing informational needs for cancer patients, assessment of the willingness to help others to stop smoking (cancer prevention), psychological scale development pertinent to intervening on adolescents who use tobacco, and quality of life assessment in cancer patients).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-34
Application #
7618240
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-03-01
Budget End
2009-02-28
Support Year
34
Fiscal Year
2008
Total Cost
$137,196
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Jahanseir, Khadijeh; Xing, Deyin; Greipp, Patricia T et al. (2018) PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. Int J Gynecol Pathol 37:537-546
Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066

Showing the most recent 10 out of 1129 publications